SCHEMBL2197664

SCHEMBL2197664

Cc1ccc([N+](=O)[O-])cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 7/20 0.59
MAPK12 P53778 7/20 0.59
MAPK11 Q15759 7/20 0.59
MAPK14 Q16539 7/20 0.59
MAPT P10636 7/20 0.52
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
HTT P42858 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
WDR5 P61964 1/20 0.44
EGFR P00533 1/20 0.43
MAPK1 P28482 1/20 0.42
TRPV1 Q8NER1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859207 0.93 MAPK13 (0.69) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2866413 0.93 MAPK13 (0.60) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2856752 0.89 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2851981 0.86 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2850856 0.85 MAPK13 (0.57) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2855113 0.83 MAPK14 (0.71) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2198681 0.83 MAPK14 (0.63) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2199480 0.83 MAPK13 (0.63) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2198207 0.83 MAPK13 (0.60) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2201626 0.82 MAPK13 (0.62) MAPK13MAPK12MAPK11MAPK14MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293772-B2 Triazole substituted aminobenzophenone compounds LEO PHARMA A/S (DK) 2012-10-23 US disclosed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
EP-1828148-B1 TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-01-20 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
US-20060128766-A1 Triazole substituted aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128766-A1 Triazole substituted aminobenzophenone compounds NFKBIA, UACA, CYP1B1 MAPK13 1436/4885MAPK12 1829/4885MAPK11 919/4885
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.